<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665232</url>
  </required_header>
  <id_info>
    <org_study_id>San Carlo Public Hospital</org_study_id>
    <nct_id>NCT04665232</nct_id>
  </id_info>
  <brief_title>Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases</brief_title>
  <official_title>Immunomodulatory Effects of Subcutaneous Progesterone in Patients Undergoing IVF Affected by Autoimmune Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Carlo Public Hospital, Potenza, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Carlo Public Hospital, Potenza, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the immunomodulatory effects of subcutaneous progesterone in patients&#xD;
      undergoing IVF by determination of anti-nuclear antibodies (ANA),extractable nuclear antigen&#xD;
      antibodies (ENA),anti- neutrophil cytoplasmic antibodies(ANCA),anti-DNA antibodies,&#xD;
      anti-cardiolipin antibodies (ACA),Lupus anticoagulant antibodies (LAC) and C3 and C4&#xD;
      fractions of complement on the day of beta hCG dosage and during the eigth week of gestation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aqueous progesterone preparation for s.c. injection is the first systemic progesterone of&#xD;
      its kind for the provision of luteal phase support (LPS) in patients undergoing IVF.&#xD;
&#xD;
      The the high solubility and rapid absorption of the new preparation are enhanced using&#xD;
      cyclodextrins that are starch residues with no therapeutic activity and with a particular&#xD;
      molecular structure that closely resembles a 'cap'.&#xD;
&#xD;
      Once absorbed after injection, the progesterone molecule is immediately dissociated from its&#xD;
      cyclodextrin 'cap', remaining free in the circulation as if produced endogenously by the&#xD;
      ovaries.&#xD;
&#xD;
      In comparison to progesterone-in-oil preparation, the new aqueous solution administered by&#xD;
      s.c.route resulted in a 3 fold higher and more rapid progesterone peak serum concentrations.&#xD;
&#xD;
      The immunomodulating effects of progesterone are mediated outside of the pelvic cavity, on&#xD;
      the peripheral cell of the immune system. For this reason only the injection procedure has&#xD;
      this advantage Furthermore, the faster absorption rate and the higher peak serum&#xD;
      concentration should increas the systemic immunomodulatory effect of subcutaneous&#xD;
      progesterone compared to the vaginal and intramuscular administration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Rate percentage, Implantation Rate percentage, Live Birth Rate percentage</measure>
    <time_frame>After two weeks from oocytes retrieval until the birth of baby</time_frame>
    <description>number of pregnancies / 100 embryotransfer, number of implanted embryos/ number of embryos trafsferred, number of live birth</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Patients affected by autoimmune diseases</arm_group_label>
    <description>Infertile patients suffering from autoimmune diseases to be subjected to IVF in which the luteal phase has been supplemented with 25 mg /die of aqueous subcutaneous progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aqueous subcutaneous progesterone</intervention_name>
    <description>25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.</description>
    <arm_group_label>Patients affected by autoimmune diseases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infertile patients affected by autoimmune diseases undergoing IVF&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infertile patients affected by autoimmune diseases undergoing IVF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  infertile patients without autoimmune diseases, fertile patients affected by&#xD;
             autoimmune diseases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assunta Iuliano, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Carlo Public Hospital, Potenza, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assunta Iuliano</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fertstert.org</url>
    <description>Hormonal induction of endometrial receptivity,Richard J. Paulson, M.D.,Fertil Steril 2011,96:530-5</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>A randomized trial comparing the endometrial effects of daily subcutaneous administration of 25 mg and 50 mg progesterone in aqueous preparation,Dominique de Ziegler,M.D., Fertil Steril 2013,100:860-6.</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>The clinical relenance of luteal phase deficiency: a commitee opinion, The practice Commitee of American Society for Reproductive Medicine, Fertil steril 2012; 98.1112-7</description>
  </link>
  <link>
    <url>http://www.rbmonline.com</url>
    <description>The luteal phase after 3 decades of IVF: what do we know? HM Fatemi, Vol.19 Suppl. 4, 2009 Reproductive BioMedicine Online</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in vitro fertilization: a non inferiority randomized study, Gillian Lockwood MD, Fertil Steril 2014, 101:112-9</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>17 Estradiol and progesterone do not influence the production of cytokines from lipopolysaccharide-stimulated monocytes in Annechien Bouman, M.D.,humans,FERTILITY AND STERILITY VOL. 82, SUPPL. 3, OCTOBER 2004</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>Glycodelin is present in pinopodes of receptive-phase human endometrium and is associated with down-regulation of progesterone receptor B, Anneli Stavreus-Evers, Fertil Steril 2006;85:1803-11.,</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>The role of T-helper cytokines in human reproduction, Kelvin J.H. Lim, Fertil and Steril VOL. 73, NO. 1, JANUARY 2000</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>The immune response during the luteal phase of the ovarian cycle: a Th2-type response?, Marijke Faas Ph.D., FERTILITY AND STERILITY VOL. 74, NO. 5, NOVEMBER 2000</description>
  </link>
  <link>
    <url>http://www.fertstert.org</url>
    <description>Environmental immune disruption: a comorbidity factor for reproduction?,Sherry E. Rier, Ph.D.,Fertil Steril 2008;89:e103-8.</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Carlo Public Hospital, Potenza, Italy</investigator_affiliation>
    <investigator_full_name>Assunta Iuliano, MD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>autoimmune diseases and infertility</keyword>
  <keyword>luteal supplementation with subcutaneous progesterone</keyword>
  <keyword>Systemic effect of progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We have a register which shows the number of the medical record of the patient</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

